Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Liquid Biopsy and Glioblastoma

Version 1 : Received: 17 December 2022 / Approved: 20 December 2022 / Online: 20 December 2022 (09:00:47 CET)

A peer-reviewed article of this Preprint also exists.

Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121. Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121.

Abstract

Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTC), or extracellular vesicles (EV) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.

Keywords

Liquid biopsy; glioblastoma; GBM; cfDNA; ctDNA; brain tumor; MRD; monitoring; CTC; treatment response

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (1)

Comment 1
Received: 13 March 2023
Commenter:
The commenter has declared there is no conflict of interests.
Comment: Here is the published version (peer-reviewed):

https://doi.org/10.37349/etat.2023.00121
Unfortunately, neither preprints, nor the publishing journal were really able to help to update it.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.